The latest anti-cancer news in 2024: Is Eculizumab included in medical insurance?

Eculizumab (Eculizumab) is a complement inhibitor and a recombinant humanized monoclonal IgG2/4κ antibody. The patented drug Eculizumab received relevant approval from the National Medical Products Administration in 2023 for sale in China, and is sold under the name Eculizumab Injection (Soliris). It is a sterile, transparent, colorless, preservative-free 10 mg/mL intravenous infusion solution packaged in 30 mL single-dose vials.

After being launched in China, eculizumab has also entered the scope of Class B medical insurance through the relevant regulations of the National Medical Insurance Administration. Reimbursement is limited to eligible patients, including patients with paroxysmal nocturnal hemoglobinuria (PNH), patients with atypical hemolytic uremic syndrome (aHUS), and adult patients with anti-acetylcholine receptor (AChR) antibody-positive refractory generalized myasthenia gravis (gMG). Patients who meet the above conditions can use medical insurance for reimbursement. Patients who do not meet the conditions but need to use eculizumab can only purchase it at their own expense.

Eculizumab, a generic drug that is marketed in China and included in medical insurance, can only be reimbursed by qualified patients. The specification is 300mg (30ml). The price of each box may be more than 3,000 yuan, which is relatively expensive. It is understood that the price of each box of the original Eculizumab drug sold overseas is more than 6,000 US dollars (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold at home and abroad are basically the same, and the price of the original drug is still relatively expensive. There are currently no generic versions of eculizumab available on the market.